![[dr. bob]](/dr-bob-sm.gif)
Dr. Bob is Robert Hsiung, MD,
bob@dr-bob.orgShown: posts 1 to 5 of 5. This is the beginning of the thread.
Posted by ben on July 7, 2005, at 8:19:53
Double-blind, placebo-controIled, multicenter study evaluating nemifitide, a now pentapeptide antidepressant, when given daily or every other day for three weeks in the treatment of major depressive disorder
J.P. Feighner, L. Sverdlov*, I Hlavka, G. Nicolau,
G. Tonelli, J. Freed. Innapharma, Inc., Park Ridge, NJ,
USA
Purpose: In previous Phase II clinical trials with nemifitide, significant antidepressant effect has been noted when giving 5-10 subcutaneous doses over one to three weeks. Recent preclinical experience with the Flinders Sensitive Line Rat Model (Dr. David Overstreet) demonstrates that every other day dosing is as good as daily dosing in predicting robust behavioral changes, consistent with antidepressants in this model This new proof of principle study is designed to evaluate the efficacy of nemifitide given either daily or every other day versus placebo over a three-week treatment period in subjects diagnosed with major depressive disorder.Method: Ninety-five subjects, at six different centers (principal investigators: Drs. John Carman, Daniel Grosz, Murray Rosenthal, Raj Rajani, Ward Smith, and Michael Liebowitz) were randomized to one of three treatment groups. All subjects received 15 subcutaneous doses Monday through Friday over three weeks with 160 mg of nemifitide (group 1), or placebo (group 2), or 160 mg of nemifitide every other day on Monday, Wednesday and Friday with placebo doses on Tuesday and Thursday for a total of nine active doses and six placebo doses (group 3). The follow up period after the end of treatment was three weeks for assessment of clinical response. The main inclusion criteria were diagnosis of major depressive disorder according to DSM-IV, baseline MADRS >25 and CGI (severity of illness) >4 at screening and at baseline (pre-dose). The exclusion criteria were standard for a clinical trial for major depression. The primary efficacy variable was MADRS (change from baseline). The secondary efficacy variables were HAMD-17 17, Carroll Self-Rating Depression Scale and CGI. The safety profile was based on adverse events, concomitant medication, vital signs, physical exams, ECG, and clinical laboratory evaluations.
Results: The study demonstrated the statistical superiority of the 160 mg dose given every other day over placebo on multiple ratings scales at multiple time points throughout the study. The 160 mg dose of nemifitide given daily Monday through Friday for three weeks was not significant in separating from placebo. Safety results provided no evidence of significant adverse events associated with the administration of nemifitide and the side effects from nemifitide were comparable to those from placebo, There were no dropouts because of significant side effects.
Conclusions: Data from this new proof of principle clinical trial provides confirmation that nemifitide has the potential to be a safe and effective antidepressant drug. The results from this study support every other day dosing of 160 mg of nemifitide over three consecutive weeks to be an effective regimen.
I think these are good news but in which phase of development is nemefitide now ? Phase II or phase III ? Nemefitide could be a superior antidepressant, but what is about pricing and application (subcutaneous is probably expensive). And we should think on other drugs with potential to be superior antidepressant like saredutant from Sanofi-Aventis. Probably saredutant will be in pharmacys in lat 2007 or early 2008. Nemefitide looks like to reach the market 2-3 years later. That could be too late, if sareduntant is as good as nemifitide and probably cheaper !Whats your opinion ?
Ben
Posted by Denise1966 on July 7, 2005, at 9:06:18
In reply to Good news about nemefitide !?, posted by ben on July 7, 2005, at 8:19:53
Hi Ben,
I spoke to Innapharma yesterday, got an update on Nemifitide and posted it on this board.
I just looked at the study you've posted and don't understand the bit where it says "The 160 mg dose of nemifitide given daily Monday through Friday for three weeks was not significant in separating from placebo" does that mean there was not difference between these two groups? You would have thought there would have been at least some difference or am I misreading it?
Kind Regards.........Denise
Posted by ben on July 9, 2005, at 2:08:30
In reply to Re: Good news about nemefitide !?, posted by Denise1966 on July 7, 2005, at 9:06:18
> Hi Ben,
>
> I spoke to Innapharma yesterday, got an update on Nemifitide and posted it on this board.
>
> I just looked at the study you've posted and don't understand the bit where it says "The 160 mg dose of nemifitide given daily Monday through Friday for three weeks was not significant in separating from placebo" does that mean there was not difference between these two groups? You would have thought there would have been at least some difference or am I misreading it?
>
>
>
> Kind Regards.........DeniseHi Denise
This means nemefitide is only superior to placebo when it is given every other day - not when it is given daily! I know that it sounds strange but if we can`t explain it we should lokking forward either. The good news is that it works in a form of application.
Best regards
Ben
Posted by ben on July 9, 2005, at 2:11:28
In reply to Good news about nemefitide !?, posted by ben on July 7, 2005, at 8:19:53
Hi Ed :-)
What is your opinion about nemefitide? Some inputs from a profi
like you ?Kind regards
Ben
Posted by ed_uk on July 9, 2005, at 7:47:21
In reply to Re: Good news about nemefitide !? » Denise1966, posted by ben on July 9, 2005, at 2:08:30
Hi Ben :-)
>This means nemefitide is only superior to placebo when it is given every other day - not when it is given daily!
I think it probably does work if it's given daily........sometimes clinical trials just don't work out eg. some clinical trials have shown SSRIs to be no better than placebo in treating depression - but many clinical trials have shown them to be effective so we can assume that they are. I think nemifitide probably works just as well regardless of whether it's given daily or on alternate days. Giving it on alternate days would be cheaper and more convenient though. It would be even better if we could give it less frequently than every other day! I wonder whether that would be effective?
Kind regards
~Ed
This is the end of the thread.
Psycho-Babble Medication | Extras | FAQ
Dr. Bob is Robert Hsiung, MD,
bob@dr-bob.org
Script revised: February 4, 2008
URL: http://www.dr-bob.org/cgi-bin/pb/mget.pl
Copyright 2006-17 Robert Hsiung.
Owned and operated by Dr. Bob LLC and not the University of Chicago.